BioSpace News Archive

Polyphor AG a research driven clinical stage, Swiss biopharmaceutical company committed to discovering and developing best-in-class molecules in oncology and antimicrobial resistance announced that the company will present at the UBS Global Healthcare Virtual Conference, taking place May 24 -26, 2021.

CoVepiT epitopes* are selected from 11 viral protein targets designed to cover all initial and new emerging SARS-CoV-2 variants.

IsoPlexis adds Switzerland as the latest country with access to their unique functional single-cell proteomics platform, adding to their existing partnerships across Asia and Europe.

Prestige BioPharma Limited and Busan City Government announced that the two organisations have entered into a memorandum of understanding for the establishment of Research and Development centre in Busan, South Korea.

Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced changes in its operating model for the Healthcare business sector.

Michael Marks, Founding Partner for WRVI Capital, Joins the Atonarp Board and Former Berkeley Lights CFO Shaun Holt Joins as Atonarp’s Chief Operating Officer

Teleflex Incorporated, a leading global provider for healthcare supplies and services, announced that it has entered into a definitive agreement to sell a significant portion of its Respiratory business to Medline Industries, Inc.

Centogene N.V., a commercial-stage company focused on rare diseases that transforms real-world clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies, announced the appointment of Dr. Michael Motz as Chief Commercial Officer, Pharmaceuticals, who will join the company on June 1, 2021.

ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO) a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced that Jaume Pons, Ph.D., Founder, President and Chief Executive Officer and other senior executives, will participate in two upcoming virtual investor conferences.

Recro Pharma, Inc. (“Recro”; NASD: REPH ), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges for companies developing oral solid dose drug products, today announced the signing of a new development agreement with Astex Pharmaceuticals, Inc.